Advocacy / AMAC On Capitol Hill

Passage of the “Protect Medical Innovation Act”

capital-building (2)On Thursday, the U.S. House of Representatives passed H.R. 160, the Protect Medical Innovation Act, which was introduced by Rep. Erik Paulsen (R-MN). This bill repeals the 2.3% excise tax put in place by ObamaCare that has had a disastrous impact on American small businesses and manufacturers that produce life-saving medical devices used every day by doctors and patients. Upon passage, Ways and Means Chairman Paul Ryan (R-WI) issued the following statement:

“This tax is a prime example of ObamaCare’s flawed priorities. Taxing medical devices not only stifles innovation and threatens American jobs, but drives up health care costs and makes treatments less accessible for those who need them most. By repealing this tax, American medical innovation can refocus on encouraging discovery and finding solutions for the health challenges—and emergencies—so many Americans face. I applaud Rep. Paulsen for his work on this legislation, and I’m proud to support it.”

AMAC is very pleased to see that H.R. 160 passed with bipartisan support, and we thank the 7,400 AMAC members who called and emailed their Representatives to unburden the public from this harmful ObamaCare tax. Your participation in the legislative process remains immensely important, and we look forward to engaging the AMAC membership in future call-to-action campaigns when issues significant to seniors arise!

 

If You Enjoy Articles Like This - Subscribe to the AMAC Daily Newsletter!

Sign Up Today
Read more articles by Caroline Rayburn
Subscribe
Notify of
5 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
Leland Kendrick MD
5 years ago

Only Idiots would kill innovation in medicine. It actually should be encouraged. we also should not let inferior generics on the market with the big lie Generics(oral) are just as good as trade name meds. I was a Pharmacist for 8 years and Know the importance of Comparing apples to apples. Inferior generics that do not mimic Bioavaliabilty can mean non controll of BP,depression,stroke etc. and generic companies boast we are cheaper because we don’t do expensive research, I suppose just wait to innovators hard work.(leaches) they should pay royalties to innovators but if inferior absorbtion etc to trade name… Read more »

Janice Munkres
5 years ago

I am SOOOO PROUD of our House members for passing H.R. 160. Now if we can just do the same with H.R. 1190! These two have been true “works of art” of our alleged President! Bit by bit, maybe we can keep him “at bay” until the end of his “tenure of terror”! Thank you AMAC for all you have done and do for we Senior Citizens!

Janice (Jan) Munkres

HAM
5 years ago

Waiting to see how it fares in the Senate. Will enough Dem’s vote for it to get the needed 67 veto proof votes? Time will tell but I, for one, won’t hold my breath. Obama WILL veto it IF it’s passed and sent to his desk. Will it be an orchestrated vote by Dem’s so the vulnerable ones can say, “don’t blame me, I voted FOR it”, so they can play the game with their constituents? OR so the Dem’s can say “see, we are willing to work in a bi-partisan way” to get bills passed? Obama has nothing to… Read more »

5
0
Would love your thoughts, please comment.x
()
x